Drug intelligence / Profile preview

HR020602

Development stage: Phase 2
Lead developer: Jiangsu Hengrui Medicine
Administration: Injection

Overview

HR020602 is an investigational drug developed for use in the induction and maintenance of general anesthesia, typically in combination with sedative anesthetics such as propofol. Its precise mechanism of action has not been disclosed or remains unknown. The drug is administered by injection and has been studied primarily in China, including a completed Phase 2 clinical trial evaluating its pharmacokinetics, safety, and efficacy in children undergoing general anesthesia. As of now, it has not received regulatory approval for any indication.

Other names: HR-020602HR020602HR 020602

Beyond the preview

Go deeper on HR020602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HR020602.

Explore the full profile